Pages that link to "Q36745251"

The following pages link to CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection (Q36745251):

Displayed 50 items.

• Role of PD-1 in HIV pathogenesis and as target for therapy (Q24634293) ‎ (← links)
• Prevention of HIV-1 infection with early antiretroviral therapy (Q24634688) ‎ (← links)
• Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? (Q26777866) ‎ (← links)
• Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis (Q26828443) ‎ (← links)
• Gut Microbiota in HIV Infection: Implication for Disease Progression and Management (Q27014742) ‎ (← links)
• Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV (Q28079826) ‎ (← links)
• The end of AIDS: HIV infection as a chronic disease (Q28300749) ‎ (← links)
• Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study (Q28475281) ‎ (← links)
• Modeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimes (Q28484046) ‎ (← links)
• Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort (Q33611305) ‎ (← links)
• Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa (Q33707759) ‎ (← links)
• Microbial translocation and cardiometabolic risk factors in HIV infection (Q33713895) ‎ (← links)
• Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model (Q33716535) ‎ (← links)
• Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study (Q33781469) ‎ (← links)
• Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy (Q33786846) ‎ (← links)
• When to start antiretroviral therapy (Q33799012) ‎ (← links)
• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI (Q33803473) ‎ (← links)
• The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment (Q33813372) ‎ (← links)
• Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015 (Q33880384) ‎ (← links)
• AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment (Q33888740) ‎ (← links)
• Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals (Q33917180) ‎ (← links)
• Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database (Q33933071) ‎ (← links)
• Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients (Q33987654) ‎ (← links)
• Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals (Q33991362) ‎ (← links)
• Residual immune dysregulation syndrome in treated HIV infection (Q34020121) ‎ (← links)
• HIV infection, inflammation, immunosenescence, and aging (Q34150710) ‎ (← links)
• Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa (Q34170487) ‎ (← links)
• Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. (Q34201445) ‎ (← links)
• Technical performance evaluation of the MyT4 point of care technology for CD4+ T cell enumeration (Q34206695) ‎ (← links)
• Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia (Q34266281) ‎ (← links)
• Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations (Q34321843) ‎ (← links)
• Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection (Q34396067) ‎ (← links)
• Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection (Q34423991) ‎ (← links)
• VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics (Q34456352) ‎ (← links)
• Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection (Q34477711) ‎ (← links)
• Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System (Q34564981) ‎ (← links)
• Immunologic basis of cardiovascular disease in HIV-infected adults (Q34638205) ‎ (← links)
• Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective (Q34650866) ‎ (← links)
• Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America (Q34736194) ‎ (← links)
• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response (Q34743336) ‎ (← links)
• When to start antiretroviral therapy: the need for an evidence base during early HIV infection (Q34773308) ‎ (← links)
• The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial (Q34812071) ‎ (← links)
• Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment (Q34937231) ‎ (← links)
• Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. (Q35030752) ‎ (← links)
• HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels (Q35057427) ‎ (← links)
• Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis (Q35063571) ‎ (← links)
• Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial (Q35074381) ‎ (← links)
• Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection (Q35082803) ‎ (← links)
• Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients (Q35087069) ‎ (← links)
• CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts (Q35175359) ‎ (← links)